1,734 karma · joined March 10, 2011
currently @ boltz bio, former yc founder
zachocean.com
- How have things looked since passage? Has there been a lot of interest from companies and patients or is demand the bottleneck? Not that many people in Montana...
- What sort of new business models does this open up? e.g. Roivant for abandoned phase 1 assets?
- Does this lower the barrier for treating new indications, e.g. age related conditions like sarcopenia?
- Any particular rules on telehealth?
Long but totally heartbreaking.
BTW: when you say you manufacture the drugs, I assume that means you're buying from an API supplier, but do you actually mean you're synthesizing it yourself?
You can also do this if you're not shutting down, but it's probably not worth it.
I'm not open-minded to arguments about utility, given that I personally witnessed LLMs evolve from interesting but useless toys to insanely helpful tools I use every day.
But from the article I linked back in March 2024:
"Generative AI models are expensive and compute-intensive without providing obvious, tangible mass-market use cases. Murati and Altman's futures depend heavily on keeping the world believing that development and improvement of their models' capabilities will continue a rapacious pace of progress that has unquestionably slowed, with OpenAI admitting that GPT-4 may be worse on some tasks.
As I've written before, hallucinations are a feature not a bug. These models do not "know" anything. They are mathematical behemoths generating a best guess based on training data and labeling, and thus do not "know" what you are asking it to do. You simply cannot fix them. Hallucinations are not going away."
Since then:
- hallucinations are dramatically less of a problem
- several mass market use cases have emerged, most notably coding
- rate of progress has increased
There may be high retention use cases that find ways to serve user needs without embarrassing them.
I don't think you can ship a fully baked product made exclusively with AI coding yet. But it's *really* useful for investigative product development - e.g. when you have a few different ideas for how something might work but aren't quite sure what's best. I used to regret that I never mastered Figma or other mockup tools - now I never will have to.
YC lists all their companies here: https://www.ycombinator.com/companies.
Many companies are likely happy to take your small check if you are a nice person and can be even minimally helpful to them. Note that for YC companies you'll probably have to swallow the pill of a $20M valuation or so.
- Gusto, Rippling, and Deel
- Mixpanel, Amplitude, Posthog